Repros Therapeutics Inc. today announced that it has entered into a definitive agreement under which Allergan plc will acquire Repros for a cash payment of $0.67 per share.
Bellicum Pharmaceuticals, Inc. today announced data highlighting results from three preclinical studies of its controllable switch technology for T cell immunotherapies.
Bellicum announced results from a leading European transplant center participating in the BP-004 trial in children with blood cancers and nonmalignant disorders.
LivaNova, a market-leading medical technology company, today announced it has entered into an agreement to acquire the remaining outstanding interests in ImThera Medical, Inc.
Moleculin announced the Investigational New Drug application for a Phase I trial of Moleculin’s drug WP1066 in patients with recurrent malignant glioma and brain metastasis from melanoma has been allowed by the U.S. FDA.
Moleculin Biotech, Inc., a clinical stage pharmaceutical company focused on the development of anti-cancer drug candidates, announced today Walter Klemp, Chairman and CEO, and Jonathan Foster, CFO, will present at the 10th Annual LD Micro Main Event on Tuesday, December 5, 2017.
LivaNova and MicroPort Scientific Corp today announced the sale of LivaNova’s Cardiac Rhythm Management Business Franchise to MicroPort for $190 million in cash.
Moleculin Biotech, Inc., a clinical stage pharmaceutical company focused on the development of anti-cancer drug candidates, announced the appointment of Dr. Sandra Silberman as Chief Medical Officer (“CMO”) in charge of New Products.